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Abstract
Background and Aim
Childhood cancer survivors are at high risk of long-termadverse effects of cancer and its
treatment, including cardiac events. The pan-EuropeanPanCareSurFup study determined
the incidence and risk factors for cardiac events among childhood cancer survivors. The
aim of this article is to describe the methodology of the cardiac cohort and nested case-con-
trol study within PanCareSurFup.
Methods
Eight data providers in Europe participating in PanCareSurFup identified and validated
symptomatic cardiac events in their cohorts of childhood cancer survivors. Data on
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symptomatic heart failure, ischemia, pericarditis, valvular disease and arrhythmia were col-
lected and graded according to the Criteria for Adverse Events. Detailed treatment data,
data on potential confounders, lifestyle related risk factors and general health problems
were collected.
Results
The PanCareSurFup cardiac cohort consisted of 59,915 5-year childhood cancer survivors
with malignancies diagnosed between 1940 and 2009 and classified according to the Inter-
national Classification of Childhood Cancer 3. Different strategies were used to identify car-
diac events such as record linkage to population/ hospital or regional based databases, and
patient- and general practitioner-basedquestionnaires.
Conclusion
The cardiac study of the European collaborative research project PanCareSurFup will pro-
vide the largest cohort of 5-year childhood cancer survivors with systematically ascertained
and validated data on symptomatic cardiac events. The result of this study can provide infor-
mation to minimize the burden of cardiac events in childhood cancer survivors by tailoring
the follow-up of childhood cancer survivors at high risk of cardiac adverse events, transfer-
ring this knowledge into evidence-based clinical practice guidelines and providing a plat-
form for future research studies in childhood cancer patients.
Introduction
Treatment for children with cancer has improved considerably over the last decades, resulting
in better survival.[1] This success has brought to light the wide variety of late complications
and the long-term adverse effects of cancer and its treatment. Approximately 75% of childhood
cancer survivors (CCS) develop at least one chronic health condition such as long-term cardiac,
endocrine, neurologic or psychosocial effects.[2–4]
Symptomatic cardiac events (CEs) such as heart failure, cardiac ischemia, arrhythmia, peri-
carditis and valvular disease are well-known long-term side effects of treatment for childhood
cancer, which can lead to long-termmorbidity and early mortality among CCS.[5–9] Treat-
ment-related risk factors for CEs include anthracyclines and radiation therapy to fields includ-
ing the heart.[5, 6, 10–13] Other suggested risk factors are gender, age at cancer diagnosis,[5,
14] smoking habits, hypertension, diabetes mellitus[15] and genetic factors.[16, 17] The evi-
dence concerning these non-treatment related risk factors for CEs is sparse and sometimes
conflicting.
Previous studies on the evaluation of risk factors for different types of CEs are limited by
small study samples, self-reported outcomes or outcomes based on record linkage without vali-
dation. Furthermore, detailed treatment information and information on contributing risk fac-
tors, such as lifestyle, is only investigated in a few studies.[15]
Knowledge of the incidence and risk factors for specific CEs is essential, as it can contribute
to optimal follow-up care for CCS and it can inform recommendations for less toxic treatments
in future childhood cancer patients. PanCareSurFup (PanCare Childhoodand Adolescent
Cancer Survivor care and Follow-up studies (PCSF); European Union (EU)-Grant agreement
number 257505) is a collaboration of European cancer registries and clinical centres, that have
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agreed to pool their data.[18] PCSF, a 6-year study that started in 2011, aims to determine the
incidence and risk factors of second cancers, late mortality and CEs, and to develop evidence-
based clinical practice guidelines for long-term follow-up, transition to adult care and health
promotion for CCS. The objective of this article is to describe the cohorts and the methodology
of the cardiac study within the PCSF collaboration.
Methods
Cohortsof cardiac study
The cardiac study of the PCSF collaboration consists of a cohort study and a nested case-control
study including eight European data providers (DPs): France, Hungary, Italy (two data provid-
ers), the Netherlands, Slovenia, Switzerland and the United Kingdom. The national committee
protecting the confidentiality of the data (CommissionNationale de l’Informatique et des Liber-
tés) approved this study. Tudományos kutatás etikai bizottság approved this study. Comitato
Etico Interaziendale A.O.U. Città della Salute e della Scienza di Torino—A.O. OrdineMauri-
ziano—A.S.L. TO1 approved this study. Comitato Etico Regione Liguria III Sezione (pediatrica)
approved this study. Institutional ReviewBoard of the AcademicMedical Center in Amsterdam
approved this study National Medical Ethics Committee of the Republic of Slovenia approved
this study. Ethics Committee of the Canton of Bern to the Swiss ChildhoodCancer Registry
approved this study. National Research Ethics ServiceUK approved this study. From the PCSF
European cohorts we included 5-year CCS in whom cancer was diagnosedbefore 20 years of age.
Methods of PCSF cardiac cohort study
Objective. The main objective of the cardiac cohort study is to determine the overall
cumulative incidence and absolute risk for symptomatic CEs in European CCS. Furthermore,
we will quantify the cumulative incidence of symptomatic CEs per childhood cancer type, dif-
ferent treatment modalities, age at treatment and calendar period of treatment. We also will
assess the influence of childhood cancer type, different treatment modalities, age at treatment
and calendar period of treatment on developing a symptomatic CE.
Primary outcomes. The CEs included in the cardiac cohort study are symptomatic heart
failure, cardiac ischemia, pericarditis, valvular disease and arrhythmia graded according to the
Criteria for Adverse Events (CTCAE)[19] as grade 3 (severe), 4 (life-threatening) or 5 (death)
(Table 1). Any CE that does not meet these criteria is graded as2. We use the extraction and
flowchart method previously described to grade the CEs.[20] To avoid introducing a potential
selection bias, we do not include asymptomatic CEs as these are mostly identified during fol-
low-up care and not all CCS will undergo follow-up-care.
Data collection for baseline characteristics. The DPs collect the following data for all
CCS included in the cohort analysis: gender, month and year of birth, month and year of first
cancer diagnosis, morphology code, topography code, laterality and basis on which the first
cancer diagnosis was made (histology, cytology, specific tumour markers or clinical investiga-
tion), and method of ascertainment of the first cancer diagnosis. In addition, the DPs collect
information on surgery (yes/no), chemotherapy (yes/no), radiotherapy (yes/no), and/or a bone
marrow transplant (yes/no), and the month and year of the start of treatment.
Statistical analyses. The outcome of interest is the occurrence of a symptomatic CE.We
will consider the time at risk to start 5 years after first cancer diagnosis. To determine the abso-
lute risk of the first occurring symptomatic CE and for the separate type of events, we will
divide the sum of the number of events by the cumulative person years/ 10,000 in the total pop-
ulation (for the whole PCSF cohort as well as for the separate data providers). We will calculate
the cumulative incidence of the first occurring symptomatic CE and of the separate types of
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CEs using competing risk analyses, with follow-up time since 5-year survival as the time scale.
Competing risk analyses take into account that members die before developing a CE. If a
cohort member died before developing a CE it was considered a competing risk. These CCS
were not censored but left in the risk set with a certain follow-up duration, depending on the
follow-up duration of CCS who did not develop a CE or did not die.[21]We will use Cox pro-
portional hazards models, with attained age as time scale, to investigate the influence of gender,
age at treatment, type of childhood cancer, type of treatment modality, and calendar period of
treatment for the first occurring symptomatic CE and for the separate CE types.
Methods of PCSF cardiac nested case-control study
Objective. The main objective of the nested case-control study is to determine the treat-
ment-related risk factors for developing symptomatic CEs in CCS; both to confirm earlier iden-
tified risk factors and to identify new treatment, patient, lifestyle and co-morbidity related risk
factors for CEs.
Study population. Each CCS identified in the cohort study with a validated CE is consid-
ered a “case”. “Controls” are randomly selected from survivors in the cohort study who did not
develop a CE and these are matched to cases (ratio 1:1) on DP, gender, age at first cancer diag-
nosis, calendar year of first cancer diagnosis and length of follow-up after first cancer diagnosis.
This procedure for sampling risk sets (i.e. density sampling) required controls to still be at risk
at the time when the case developed the event. Thus, the length of follow-up (starting at first
cancer diagnosis) in the control is at least that of the corresponding case. STATA (version 13,
StataCorp) is used for control selection.
Detailed treatment data collection frommedical records. In addition to the baseline
data collected in the cohort study, detailed treatment data from all cases and controls is being
collected.Data is collected from the medical records using an extraction form designed espe-
cially for PCSF (see also S1 Appendix). We collect data on the type of chemotherapy, cumula-
tive dose (in mg/m2 or equivalent) and method of administration for each chemotherapeutic
agent. For anthracyclines/ anthraquinones (doxorubicin, daunorubicin, epirubicin, idarubicin
and mitoxantrone) we also collect data on infusion duration, dose per week and whether a car-
dio-protectant (like dexrazoxane) was given concurrently. We perform dosimetry for the
Table 1. Definitionsof cardiac events (usingCTCAEv3.0 andCTCAEv4.0)*.
Grade 3 Grade 4 Grade 5
Heart failure Symptomatic CHF responsive to intervention, or
EF < 40%-20%, or SF <15%
Refractory CHF or poorly controlled; EF <20%; intervention such
as ventricular assist device, ventricular reduction surgery, or heart
transplant indicated; life threatening consequences CE*
Death due to
heart failure
Cardiac
ischemia
Symptomatic and testing consistent with
ischemia or unstable angina or intervention
needed
Myocardial infarction; life threatening consequences CE* Death due to
cardiac ischemia
Pericarditis With physiological consequences CE (e.g
pericardial constriction or pericardial effusion)
With life threatening consequences CE (e.g. hemodynamic
compromise)
Death due to
pericarditis
Valvular
disease
Symptoms of severe regurgitationor stenosis,
symptoms controlledwith interventions
Life threatening consequences CE or intervention (e.g. valve
replacement or valvuloplasty) indicated
Death due to
valvular disease
Arrhythmia Symptomatic and incompletely medically
controlled or controlledwith device (e.g.
pacemaker, ICD or CRT)
Life threatening consequences CE (e.g. arrhythmia associated with
CHF, hypotension, syncope, shock)
Death due to
arrhythmia
*as reported in the Criteria for Adverse Events (CTCAE)v4.0
CHF = congestive heart failure; EF = ejection fraction; SF = shortening fraction; ICD = implantable cardioverse defibrillator; CRT = cardiac resynchronisation
therapy
doi:10.1371/journal.pone.0162778.t001
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whole body including seven points in the heart for all cardiac cases and controls who received
radiotherapy, as previously described.[22] Furthermore, multiple imputation methodologywas
used when information was missing.
Detaileddata collection frommedical record and questionnaire. We collect data on
potential confounding factors including congenital heart disorders (e.g. atrial/ ventricular sep-
tum defect, bicuspid aortic valve), hypercholesterolemia treated with medication, hypertension
treated with medication, diabetes mellitus treated with medication or diet, clotting disease
(protein S or C deficiency), thyroid disease treated with medication, pregnancies, lung trans-
plant, kidney transplant, height, weight, waist circumference, hip circumference, family history
of cardiac disease, physical activity, type of occupation, smoking and medication use.We col-
lect these possible confounding factors by using questionnaires completed by patients or their
families and subsequently DPs enter the data in a secure online database.
Collectionof biomaterial. DNA data is being collected from the cardiac cases and cardiac
controls that were alive and it is stored in the country of the DPs for future use. Blood samples
are requested from CCS who visit an outpatient clinic and saliva/oral epithelial cells are
requested by mail for those CCS who are not visiting an outpatient clinic, or for those CCS
who received an allogeneic stem cell transplant.
Statistical analyses. For the separate types of CEs we will analyse the following covariates
in our models: gender, age at primary childhood cancer diagnosis and different aspects of
childhood cancer treatment (chemotherapy and radiotherapy). Since not all CEs have the same
risk factors, each model will have different covariates based on the literature and clinical
knowledge of each CE.We will investigate the role of anthracyclines [5, 6, 10, 11, 23], mitoxan-
trone [24, 25], cisplatin[26] as well as alkylating agents (as cyclophosphamide equivalence dose
(CED)[27] and separate types of alkylating agents such as cyclophosphamide[28, 29]) as risk
factors for CEs.We will also investigate the role of radiation therapy where the heart was part
of the field[5, 6, 12, 13] and the role of cranial radiation therapy.[30, 31] The covariates and
confounding factors will be considered in a conditional multivariate linear logisticmodel to
control for pairwisematching in case-control studies.[32]
Results
Cohortsof cardiac study
In Table 2 the different cohorts are described.The PCSF cohort consisted of 59,915 5-year CCS
with malignancies diagnosed between 1940 and 2009. Diagnoses were classified according to
the International Classification of ChildhoodCancer 3.[33]
Primaryoutcome
The ascertainment of the CEs is described in Table 3. Different strategies were used to identify
CEs: linkage to population/hospital or regional based databases (hospitalizations, medication
use, general practitioner (GP) visits) as well as patient and GP based questionnaires. To obtain
more information for the validation of the CEs, five DPs retrieved information from the medi-
cal records and the GP, and two DPs used the medical records and one used (telephone) ques-
tionnaires. Five of the eight DPs used the flowchart extractionmethod (20) to validate and
grade the CEs. Cohort and nested case-control studies will be published separately.
Discussion
PCSF is an ongoing EU-funded collaborative research project investigating late effects in
5-year CCS. The cardiac study of PCSF examines cardiac late effects in a large cohort and in a
Late Cardiac Events after ChildhoodCancer:Methodology of a Pan-European Study
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nested case-control study with data from eight European DPs. The current manuscript
describes in detail the methodologyof this cardiac study and we highlight the unique features
of this large Pan-European partnership. We believe that the cohort size and the chosenmeth-
odology of the cardiac study of PCSF will provide new evidence concerning risk factors of CEs
in CCS.
The PCSF collaboration will add new knowledge to that gained in previously published
studies.[5, 6, 8, 23, 34–37] In the past, CEs have been described in 3 types of studies. First, sin-
gle-centre studies have assessed the incidence and risk factors of CEs in CCS. [6, 23, 36] Some
of these studies have an almost complete follow-up and good outcome validation. However,
Table 2. Inclusion criteria for each data provider withinPCSF.
Type of cohort (>5 year survivors) Number of childhood
cancer survivors in
cohort
Age at primary
cancer diagnosis
Type of
malignancy
Period of primary
cancer diagnosis
France Hospital data (5 paediatric oncology centres),
clinical trials, and cancer registry (ongoing)
3,097 0-<21 years Solid tumours 1940–1986
Hungary Hospital data, clinical trials, and nationwide
cancer registry (ongoing)
5,162 0-<18 years All, including
benign CNS
tumours
1971–2008
Italy (hospital
based)
Nationwide cancer registry 3,004 0-<15 years All 1960–2008
Italy
(population
based)
CCRP (ChildhoodCancer Registry of
Piedmont) and AIRTUM (Italian Association of
Cancer Registries)
15,124 0-<18 years All 1967–2009
The
Netherlands
DCOGLATER (= Dutch ChildhoodOncology
group Long-termeffects) registry based on
Nationwide hospital based cohorts
6,087 0-<18 years All 1964–2001
Slovenia Nationwide Slovenian cancer registry, follow-
up clinic
2,341 0-<16 years All 1961–2002
Switzerland Nationwide Swiss ChildhoodCancer Registry 4,718 0-<21 years All, and LCH 1964–2005
United
Kingdom
Nationwide cancer registration 17,981 0-<15 years All 1940–1991
CNS = central nervous system; LCH = LangerhansCell Histiocytosis; PCSF = PanCareSurFup
doi:10.1371/journal.pone.0162778.t002
Table 3. Cardiac outcome ascertainment per data provider withinPCSF.
Data provider Methodof identification of potential cardiac events Source of additional information to
validate cardiac events
France Questionnaires to patients/ medical records Questionnaire/Telephone
Hungary Visit to follow up clinic/ Medical records + GP
questionnaires to patients
Italy (hospital
based)
Linkage: hospitalization database Medical records
Italy (population
based)
Hospital discharge database, medical records, questionnaire to patients Medical records
The Netherlands Questionnaires to patients or GP/Visit to follow up clinic/ medical records Medical records + GP
Slovenia Visit to follow up clinic/ questionnaires to patients Medical records + GP
Switzerland Visit to follow up clinic/ questionnaires to patients/ Linkage with death registry Medical records + GP
UnitedKingdom Questionnaires to patients/ linkage: different hospital episode databases (outpatient
+ in patient + emergency care + death registry)
Medical records + GP
GP = general practitioner; PCSF = PanCareSurFup
doi:10.1371/journal.pone.0162778.t003
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due to their small sample sizes, these studies are not able to examine risk factors for all types of
CEs.[6, 23, 36] Second,multicentre studies with large study populations have performed risk
factor analysis per specific CEs, but these have mainly analysed self-reported outcomes that
could be at risk of outcome reporting bias.[5, 35] Finally, nationwide studies using medical
record linkage have a large study population with complete follow-up and a diminished risk of
selection and outcome report bias [34, 38]. Nevertheless, they usually lack detailed treatment
information. These missing data can prevent the possibility of performing an in-depth treat-
ment related risk factor analysis.[34, 38] In contrast, PCSF addresses the incidence and risk fac-
tors of symptomatic CEs in a design that carries minimal risk of bias due to the method of
ascertainment and extensive validation of CEs, as well as benefiting from detailed information
on treatment.
Essential to the development of this project is the close collaboration between investigators
of several European countries that provides systematically ascertained and validated data on
symptomatic CEs. A potential drawback is that the differences in inclusion criteria and method
of identification of potential CEs might mean that the data is too heterogeneous to pool. One
of the main objectives of the cardiac component of PCSF is to adequately identify all potential
risk factors for CEs. This is especially important for less frequent CEs for which we currently
have only a small amount of data on risk factors. To adequately identify potential risk factors
we need sufficient numbers for the separate types of CEs. Studies have shown that the number
of outcome events are accountable for the number of covariates (potential risk factors) in the
Cox proportional hazard model.[39] Less than 10 events per covariate in the results of the Cox
proportional hazard should be interpreted with caution. We estimate that we will have 750 car-
diac cases in the case-control study. Applying the classification of CE types describedby a sin-
gle centre clinical cohort study [6], we can estimate the number of the different types of CEs
that we will have in our case-control study (Table 4). Hence, a strength of our study is that the
final number of the different types of CEs will be sufficient for adequate risk factor analyses
and safe interpretation.
Previous studies have suggested a possible association between genetic factors and CEs.[16,
17] Thus, the DNA that PCSF is collecting from all the cardiac cases and cardiac controls in
combination with the detailed information on the CCS will be a valuable source of information
for future research. Furthermore, PCSF has focused on developing evidence-based long-term
follow-up guidelines in collaboration with the International Guideline Harmonization group.
[40] These guidelines will be used to guide survivors and health care providers on, amongst
others, the prevention, early detection and treatment of long-term effects of childhood cancer.
The recently published clinical practice guideline on cardiomyopathy surveillance for CCS
Table 4. Estimated numbers of the separate types of CEs based on the assumption of 750 cardiac
cases.
Estimatednumber of each type of cardiac adverse event
Heart failure* 405
Cardiac Ischemia* 90
Pericarditis* 30
Valvular disease* 90
Arrhythmia* 135
*estimation based on van der Pal 2012: 54% heart failure, 12% cardiac ischemia, 4% pericarditis, 12%
valvular disease and 18% arrhythmia.
CE = cardiac event
doi:10.1371/journal.pone.0162778.t004
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notes the existing gaps in knowledge to improve cardiovascular health of CCS.[41] Armenian
and colleagues highlighted the need for multidisciplinary and international collaboration with
access to large populations in order to fill in these current research gaps.[41] Therefore, the
findings of the cardiac cohort and nested case-control study of PCSF will be an important
source of evidence and will provide an information base for long-term cardiac follow-up guide-
lines of CCS.Moreover, the successful identification of risk factors associated with the develop-
ment of CEs can inform the further development of less cardiotoxic treatment for childhood
cancer patients.
In conclusion, the cardiac studies included within the PCSF project benefit from the largest
cohort of 5-year CCS with detailed treatment information and systematic ascertainment and
validation of CEs. In order to achieve tailored follow-up of CCS at risk of CEs, the large number
of individuals in PCSF will allow to adequately identify risk factors for different types of symp-
tomatic CEs and incorporate this knowledge into evidence-basedclinical practice guidelines
for long-term follow-up of childhood cancer patients.
Supporting Information
S1 Appendix. Data collection form chemotherapy.
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